Protara Therapeutics (TARA) Profit After Tax (2013 - 2026)
Protara Therapeutics (TARA) posted quarterly Profit After Tax of -$17.8 million for Q1 2026, down 49.25% year-over-year from -$35.0 million in Q1 2025, and down 2.74% quarter-over-quarter from -$17.3 million in Q4 2025.
Protara Therapeutics (TARA) Profit After Tax (2013 - 2026) Analysis & Trends
Protara Therapeutics (TARA) has reported Profit After Tax for 14 consecutive years, with -$17.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax fell 49.25% year-over-year to -$17.8 million; the TTM figure through Mar 2026 stood at -$63.3 million (down 39.3% YoY), while the FY2025 annual figure was -$57.4 million, down 28.8% from the prior year.
- Profit After Tax eased to -$17.8 million in Q1 2026 per TARA's latest filing, from -$17.3 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$7.7 million in Q3 2022 and bottomed at -$39.0 million in Q4 2022.
- Historically, Profit After Tax has averaged -$13.3 million across 5 years, with a median of -$11.2 million in 2024.
- Annual changes were most pronounced in 2022 — Profit After Tax plunged 274.68% — and 2023, when it jumped 75.46%.
- Protara Therapeutics' Profit After Tax stood at -$39.0 million in 2022, then surged by 75.46% to -$9.6 million in 2023, then tumbled by 34.14% to -$12.8 million in 2024, then slumped by 34.91% to -$17.3 million in 2025, then retreated by 2.74% to -$17.8 million in 2026.
- Business Quant data shows TARA's Profit After Tax at -$17.8 million in Q1 2026, -$17.3 million in Q4 2025, and -$13.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Protara Therapeutics | 234.56 Mn | 234.56 Mn | - | -21.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -21.67 Mn |
| Mar 31, 2026 | -17.78 Mn |
| Dec 31, 2025 | -17.31 Mn |
| Sep 30, 2025 | -13.26 Mn |
| Jun 30, 2025 | -14.96 Mn |
| Mar 31, 2025 | -11.91 Mn |
| Dec 31, 2024 | -12.83 Mn |
| Sep 30, 2024 | -11.19 Mn |
| Jun 30, 2024 | -9.51 Mn |
| Mar 31, 2024 | -11.10 Mn |
| Dec 31, 2023 | -9.56 Mn |
| Sep 30, 2023 | -9.86 Mn |
| Jun 30, 2023 | -11.29 Mn |
| Mar 31, 2023 | -9.05 Mn |
| Dec 31, 2022 | -38.97 Mn |
| Sep 30, 2022 | -7.70 Mn |
| Jun 30, 2022 | -8.54 Mn |
| Mar 31, 2022 | -10.76 Mn |
| Dec 31, 2021 | -10.40 Mn |
| Sep 30, 2021 | -10.72 Mn |